Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
Expert Review of Gastroenterology & Hepatology|May 29, 2019
Considerations of heterogeneity in clinical trials for hepatocellular carcinomaTsung-Hao Liu, Yu-Yun Shao, Li-Chun Lu, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 5, 2009
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survivalYing-Chun Shen, Fu-Chang Hu, Yung-Ming Jeng, et al.Journal for Immunotherapy of Cancer|February 20, 2025
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma modelsYing-Chun Shen, Nai-Wen Chang, Ching-Ping Yeh, et al.American Journal of Clinical Pathology|November 13, 2004
Gastric bleeding due to graft-vs-host disease: discrepancy between endoscopic and histologic assessmentSu-Peng Yeh, Yu-Mine Liao, Chang-Hu Hsu, et al.Biomedical Journal|May 20, 2026
Less Is More: A Single-Dose, Non-Waiting Neoadjuvant Immunotherapy Strategy for Hepatocellular CarcinomaKevin Kuan-Yu Chen, Tzu-Jung Lin, Te-Wei Su, et al.ACS Nano|January 23, 2023
Embedded Integration of Sb<sub>2</sub>Se<sub>3</sub> Film by Low-Temperature Plasma-Assisted Chemical Vapor Reaction with Polycrystalline Si Transistor for High-Performance Flexible Visible-to-Near-Infrared PhotodetectorYing-Chun Shen, Cheng-Yu Lee, Hsing-Hsiang Wang, et al.Journal of Hepatology|January 25, 2026
Revisiting Prophylactic Corticosteroids to Mitigate Severe Immune-Related Adverse Events in Hepatocellular CarcinomaYing-Chun Shen, David J Pinato, Tsung-Hao Liu, et al.Cancer Medicine|September 22, 2023
Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysisShang-Hsuan Peng, Ching-Hung Lin, I-Chun Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinomaDa-Liang Ou, Ying-Chun Shen, Ja-Der Liang, et al.Journal of Hepatology|February 23, 2011
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracilChao-Yu Hsu, Ying-Chun Shen, Chih-Wei Yu, et al.Pageof 6